541 related articles for article (PubMed ID: 35475341)
1. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
[TBL] [Abstract][Full Text] [Related]
2. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
[TBL] [Abstract][Full Text] [Related]
3. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J
Eur J Clin Pharmacol; 2023 Sep; 79(9):1239-1248. PubMed ID: 37449993
[TBL] [Abstract][Full Text] [Related]
4. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
[TBL] [Abstract][Full Text] [Related]
5. Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO
Diabetes Obes Metab; 2024 Jul; 26(7):2787-2795. PubMed ID: 38618983
[TBL] [Abstract][Full Text] [Related]
6. Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center.
Hamid A; Vaduganathan M; Oshunbade AA; Ayyalasomayajula KK; Kalogeropoulos AP; Lien LF; Shafi T; Hall ME; Butler J
J Cardiovasc Pharmacol; 2020 Sep; 76(3):313-320. PubMed ID: 32569016
[TBL] [Abstract][Full Text] [Related]
7. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
[TBL] [Abstract][Full Text] [Related]
8. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
[No Abstract] [Full Text] [Related]
9. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review.
Scheen AJ
Diabetes Metab; 2024 Mar; 50(2):101508. PubMed ID: 38158077
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
Edwards K; Li X; Lingvay I
J Clin Endocrinol Metab; 2023 Mar; 108(4):920-930. PubMed ID: 36268825
[TBL] [Abstract][Full Text] [Related]
13. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
14. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
15. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
[TBL] [Abstract][Full Text] [Related]
17. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies.
Hsiao FC; Yen KC; Chao TF; Chen SW; Chan YH; Chu PH
J Clin Endocrinol Metab; 2022 Aug; 107(9):2493-2499. PubMed ID: 35776065
[TBL] [Abstract][Full Text] [Related]
18. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
Cotter G; Davison BA; Edwards C; Senger S; Teerlink JR; Zannad F; Nielsen OW; Metra M; Mebazaa A; Chioncel O; Greenberg BH; Maggioni AP; Ertl G; Sato N; Cohen-Solal A
Am Heart J; 2021 Oct; 240():73-80. PubMed ID: 34107289
[TBL] [Abstract][Full Text] [Related]
19. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
[TBL] [Abstract][Full Text] [Related]
20. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
